Topical delivery of 5-fluorouracil and 6-mercaptopurine by their alkylcarbonyloxymethyl prodrugs from water: vehicle effects on design of prodrugs. 2003

Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
Department of Medicinal Chemistry, PO Box 100485, University of Florida, Gainesville, Florida 32610, USA. sloan@cop.ufl.edu

OBJECTIVE To determine whether the fluxes through hairless mouse skin for three homologous series of prodrugs of 5-fluorouracil (5-FU, 1) and 6-mercaptopurine (6-MP, 2) from saturated aqueous suspensions show dependencies on aqueous (SAQ) and isopropyl myristate (SIPM) solubilities similar to those shown by the identical compounds delivered from IPM. METHODS Flux through hairless mouse skin from water (JMAQ) and solubility data were measured for a homologous series of six 3-alkylcarbonyloxymethyl (ACOM) prodrugs of 5-FU (3-ACOM-5-FU), and five 6-ACOM-6-MP prodrugs, then combined with literature data for five bis-6,9-ACOM-6-MP prodrugs to give a data base. Multiple linear regression using SPSS 7.5 was performed on log SIPM, log SAQ, molecular weight and log JMAQ data to determine the best fit coefficients to the transformed Potts-Guy equation: log JMAQ = x + y log SIPM + (1 - y) log SAQ + z MW. Permeability coefficients (PMAQ) were calculated from JMAQ/SAQ. RESULTS The best fit coefficients for the flux from AQ(JMAQ) were x = -1.497, y = 0.660 and z = -0.00469 (r2 = 0.765) with an average error of prediction equal to 0.193 log units. The best fit coefficients for the flux from IPM (JMIPM) were x = -0.557, y = 0.536 and z = -0.00261 (r2 = 0.941) with an average error of prediction equal to 0.109 log units. For all three series, log PMAQ increased whereas log PMIPM decreased with increasing alkyl chain lengths in the promoiety and with decreasing solubility parameter values. CONCLUSIONS The transformed Potts-Guy equation can be used to predict JMAQ but with less certainty than JMIPM. SIPM and SAQ have consistently been shown to have a positive influence on JMIPM, and now on JMAQ, with a balance between the two solubilities being obviously important. The previous observation that log PMAQ increased with lipophilicity is an artifact of normalizing JMAQ by SAQ.

UI MeSH Term Description Entries
D008812 Mice, Hairless Mutant strains of mice that produce little or no hair. Hairless Mice,Mice, Inbred HRS,Mice, hr,Hairless Mouse,Mice, HRS,Mouse, HRS,Mouse, Inbred HRS,HRS Mice,HRS Mice, Inbred,HRS Mouse,HRS Mouse, Inbred,Inbred HRS Mice,Inbred HRS Mouse,Mouse, Hairless
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014677 Pharmaceutical Vehicles A carrier or inert medium used as a solvent (or diluent) in which the medicinally active agent is formulated and or administered. (Dictionary of Pharmacy, 1986) Pharmaceutical Vehicle,Vehicle, Pharmaceutical,Vehicles, Pharmaceutical
D014867 Water A clear, odorless, tasteless liquid that is essential for most animal and plant life and is an excellent solvent for many substances. The chemical formula is hydrogen oxide (H2O). (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Hydrogen Oxide
D015122 Mercaptopurine An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. 6-Mercaptopurine,1,7-Dihydro-6H-purine-6-thione,6-Mercaptopurine Monohydrate,6-Thiohypoxanthine,6-Thiopurine,6H-Purine-6-thione, 1,7-dihydro-,BW 57-323H,Leupurin,Mecaptopurine Anhydrous,Mercaptopurina Wellcome,Puri-Nethol,Purimethol,Purinethol,6 Mercaptopurine,6 Mercaptopurine Monohydrate,6 Thiohypoxanthine,6 Thiopurine,BW 57 323H,BW 57323H
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
May 2003, Journal of pharmaceutical sciences,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
January 1998, Journal of pharmaceutical sciences,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
April 2001, International journal of pharmaceutics,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
January 2002, International journal of pharmaceutics,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
August 1987, Journal of pharmaceutical sciences,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
March 1988, Journal of pharmaceutical sciences,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
February 2008, International journal of pharmaceutics,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
January 2008, International journal of pharmaceutics,
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
July 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Kenneth B Sloan, and Scott Wasdo, and Udo Ezike-Mkparu, and Thomas Murray, and Donna Nickels, and Surjit Singh, and Thea Shanks, and John Tovar, and Karen Ulmer, and Robert Waranis
November 2000, Journal of pharmaceutical sciences,
Copied contents to your clipboard!